Thymosin Alpha-1

Thymosin Alpha-1 (Tα1) is a 28-amino acid N-terminally acetylated peptide derived from prothymosin alpha. It acts primarily through TLR-2 and TLR-9 signaling pathways to activate dendritic cells, T lymphocytes (CD4+ and CD8+), and natural killer cells.

Tα1 promotes differentiation of T-cell precursors into mature T cells, enhances cytokine production (IFN-γ, IL-2, IL-10), activates dendritic cell maturation, and increases MHC class I expression on tumor cells. These effects make it relevant for immune deficiency research, viral infection models, and cancer immunotherapy support.

Tα1 is approved for clinical use in multiple countries. Research documents efficacy in chronic hepatitis B and C (immune restoration), malignant melanoma (immune adjuvant), DiGeorge syndrome (T-cell reconstitution), and COVID-19 severity reduction in clinical studies. The compound has been in clinical use for 40+ years.

Store lyophilized at -20°C. Reconstituted solution stable 28 days at 2–8°C. Tα1 is relatively stable due to N-terminal acetylation. Bacteriostatic water recommended.